Narrow these 4 — tap a value to filter:
Trait 2
Open an event to see its evidence. Attack and trait tags link to their definitions
May 1, 2026 A federal appeals court restricted access to mifepristone nationwide Corroborated Civil Rights and Dissent
The ruling narrowed practical access to abortion and miscarriage medication, affecting bodily autonomy even in states with legal protections.
Supporting reports
- Federal appeals court orders restrictions on mifepristone — A federal appeals court has ordered nationwide restrictions on mifepristone, a medication used for abortion and miscarriage care, potentially disrupting access even in states where abortion is legally protected.
- U.S. Court of Appeals for the Fifth Circuit restricts mifepristone access — On May 1, the U.S.
May 1, 2026 The DEA placed four synthetic cannabinoids into Schedule I Tier 1 · Primary Economic Structure
The rule tightened federal drug controls and expanded criminal and regulatory restrictions in response to public-health risk claims.
Supporting reports
- DEA Schedules Synthetic Cannabinoids as Schedule I Substances — The Drug Enforcement Administration (DEA) has issued a final rule placing four synthetic cannabinoids—4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA—into Schedule I of the Controlled Substances Act.
Apr 30, 2026 The FDA proposed withdrawing approval of TAVNEOS over effectiveness and data-integrity concerns Tier 1 · Primary Economic Structure
The proposal showed a regulator using its authority to revisit a drug approval when evidence and truthfulness in the application were in doubt.
Supporting reports
- FDA Proposes Withdrawal of TAVNEOS Approval — The FDA has proposed withdrawing approval for TAVNEOS (avacopan) capsules, citing lack of substantial evidence of effectiveness and untrue statements in the application.
Apr 27, 2026 EPA Administrator Lee Zeldin defended EPA deregulation and denied meetings later tied to Bayer evidence Tier 1 · Primary Economic Structure
The hearing highlighted possible agency capture and reduced accountability as environmental regulation was aligned with major corporate interests.
Supporting reports
- EPA Administrator Lee Zeldin Defends Deregulatory Agenda — EPA Administrator Lee Zeldin faced a contentious House hearing defending the agency's deregulatory agenda, which includes rolling back clean air and water standards and granting exemptions to polluting corporations.